
|Videos|July 7, 2023
ADAURA: Overall Survival Analysis of Osimertinib in NSCLC
Charu Aggarwal, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data updates from the ADAURA trial, an overall survival analysis of osimertinib in non–small cell lung cancer (NSCLC).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
3
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5


















